ClinicalTrials.gg

Program

TQB2029

A development code. Also written as “TQB2029 injection”.

In Sino Biopharmaceutical's pipeline, GPRC5D/CD3双抗. Its studies are mostly in Multiple Myeloma, led by Sino Biopharmaceutical.

Furthest: phase 1, since Nov 20, 20241 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical11 open or runningphase 1since Nov 20, 2024Nov 20, 2024none ahead
  • Named in Sino Biopharmaceutical’s own pipeline as TQB2029, phase 1, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 20, 2024First study: phase 1 study in Multiple MyelomaFirst studyNCT06700395 · 136 planned · China

TargetBeta

“GPRC5D/CD3双抗”the company's pipeline, read by Claude · source

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
ramantamigJohnson & Johnsonphase 37
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34
QLS4131ruleQilu Pharmaceuticalphase 33
QLS32015ruleQilu Pharmaceuticalphase 32
MBS314 for Injectionrulebeijing-mabworks-biotech-co-ltdphase 21
REGN17372ruleRegeneron Pharmaceuticalsphase 21

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06700395Multiple Myeloma · China1RecruitingMar 2026136

How it is read

Names in the registry

  • “TQB2029 injection”, 1 entry

Codes read as this program: TQB2029.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.